about
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanc...
Read More
3.05
-0.07
(-2.24%)
3.0M
XNAS Volume
XNAS 10 Jul, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Neutral
Altimmune Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..